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  ABSTRACT 
 
INTRODUCTION: Traumatic brain injury (TBI) is a major public health problem, 
causing approximately 52,000 deaths from 1.7 million injuries in the United States 
annually, with a combined direct and indirect economic cost estimated at $60-75 billion 
per year. Traumatic subarachnoid hemorrhage (tSAH), a subtype of closed head injury, 
has a high prevalence within TBI—evident in up to two-thirds of moderately and 
severely brain injured patients. tSAH is also associated with poor clinical outcomes; 
some research suggests mortality and unfavorable outcome rates are two-to-three times 
higher in patients with tSAH, based on brain imaging, compared to those without. To 
date, no pharmacological treatment has been conclusively shown to improve outcomes in 
humans for either moderate or severe TBI or for specific tSAH injury. The aim of this 
study was to assess whether the effect of PROG was substantially different in study TBI 
patients with evidence of tSAH on initial brain imaging compared to those that did not 
have evidence of tSAH. 
 
METHODS: ProTECT III clinical trial data was used for an exploratory, post hoc 
subgroup analysis to determine the effect of the hormone progesterone (PROG) on 
outcome. Study subjects with any abnormality on baseline brain imaging were included 
in the analysis and two subgroups, tSAH positive (+tSAH) and tSAH negative (–tSAH), 
were selected. The primary outcome evaluated was a favorable/unfavorable dichotomy 
derived from the 6-months post-injury Extended Glasgow Outcome Scale (GOSE) 
assessment, which evaluates both mortality and functional outcomes. Risk ratios (RRs) 
were calculated for the total sample and each of the two subgroups and used as statistical 
evidence for interaction between PROG and tSAH. 
 
RESULTS: All subjects from the original ProTECT III trial cohort (N=882) with no 
abnormalities found on baseline computed tomography (CT) image (n=125) or missing 
image (n=1) were excluded from this analysis. Subjects with one or more abnormalities 
noted on CT (+CT, n=756) were then divided into subgroups based on presence (n=582) 
or absence (n=174) of tSAH. Subjects with +tSAH were more severely injured than         
–tSAH (mean Rotterdam CT score 3.3 vs. 2.2; 3.1 overall) and had a lesser proportion of 
favorable outcomes (47.4% vs. 74.3%; 53.6% overall). Compared to placebo, patients 
treated with progesterone had marginally better likelihood of favorable outcomes (risk 
ratio among +tSAH 1.06, 95% confidence interval [CI], 0.89 to 1.26; and RR among       
–tSAH 1.02, 95% CI 0.85 to 1.22). A multivariable model, adjusted for baseline 
differences in treatment group covariates did not yield substantially different results for 
the effect of progesterone on favorable outcomes (+tSAH 1.07; 95% confidence interval 
[CI], 0.84 to 1.36, –tSAH 1.08; 95% CI 0.75 to 1.56, +CT 1.06; 95% CI 0.87 to 1.29).  
 
CONCLUSION: Our study demonstrated that progesterone did not result in different 
effects in patients with or without tSAH than those without based on initial brain 
imaging. This investigation supports previous research findings; tSAH is correlated with 
more severe injury and worsened outcomes. Concomitant injuries found in +tSAH group 
are likely worsening the outcomes over –tSAH, but this was not evaluated here. More 
complex statistical modeling should be used on this data to determine if it provides 
evidence that tSAH is an independent prognosticator of unfavorable outcome or merely 
associated with more severely injured patients.	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I. INTRODUCTION 
 
 Traumatic brain injury (TBI) is defined as “an alteration in brain function, or other 
evidence of brain pathology, caused by an external force” (Menon, Schwab, Wright, & 
Maas, 2010, p. 1637). TBIs can range from minor (such as a mild concussion) to 
catastrophic and sometimes fatal injuries. As the magnitude of the brain injury increases, 
so does the cost of treatment and amount of future disability associated with the injury. 
Recent evidence shows staggering figures regarding the incidence and prevalence of 
TBI; each year, just in the United States, millions of individuals are affected by brain 
injury with billions of dollars of economic impact (Langlois, Rutland-Brown, & Wald, 
2006). 
 In addition to the substantial cost of treatment and lost productivity, the burden of 
injury of TBI is massive. The most severe nonfatal cases cause permanent and profound 
morbidity, not only devastating the lives of the patients, but also those around them. The 
disruption suffered by the families and loved ones of these patients and the emotional 
impact of TBI will likely remain extremely difficult to quantify (Humphreys, Wood, 
Phillips, & Macey, 2013, p. 282). To further complicate their situation and prognosis, 
TBI patients are frequently at higher risk for a host of other harmful conditions, from 
depression and substance abuse to epilepsy and Alzheimer’s disease (Langlois et al., 
2006, p. 376). 
 Decades of research have been performed with the hope of alleviating some of this 
burden by improving diagnosis, clinical care, rehabilitation, and, consequently, the 
outcomes and quality of life attained by these patients. Although significant advances 
have been made in treatments throughout the course of the disease, from before the 
injury occurs to rehabilitation and care years later, much work remains to be done in 
virtually every area and at every stage of the trauma. Prevention and reduction of injury 
by safety devices (such as seat belts and helmets), behaviors (like geriatric fall risk 
assessments), and regulation (e.g. traffic safety measures) have undoubtedly saved 
countless lives and lessened the extent of many of the injuries suffered. No treatment 
will ever rival the avoidance of injury for the millions of TBIs sustained every year, so 
continued efforts in these endeavors is clearly warranted.  
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Clinical care has been greatly elevated as brain injury has become better 
understood. Diagnoses are made more rapidly with fast, high-resolution brain imaging 
technologies and refined, evidence-based clinical assessments. Advanced neurosurgical 
procedures and sophisticated monitoring devices are pushing our capabilities to new 
levels. Standardizing recommendations through the establishment of “best practice” 
guidelines has improved the quality and consistency of care (Carpenter et al., 2015). 
Specialized post-acute-phase facilities, such as Atlanta’s Shepherd Center, have 
revolutionized not only the efficacy of the rehabilitation delivered to patients but have 
shifted our fundamental expectations for the extent of recovery that is possible after a 
TBI has been sustained (Kunik, Flowers, & Kazanjian, 2006). 
 Perhaps the area within TBI treatment that has the most potential for a significant 
breakthrough is the pharmacological treatment of brain injury. The acute-phase care of 
patients with moderate and severe brain injury is largely focused on supporting vital 
physiologic processes during the complex biochemical changes that occur within the 
brain and body as a result of TBI. Intervening in these injury cascades, repairing 
damage, or preventing further harm is the elusive “Holy Grail” of treatment for the more 
severely brain-injured patient. Neurosurgical procedures are indicated and effective in 
certain types of TBI, and physiologic mechanisms and measurements such as blood 
pressure or serum lab values can be manipulated through pharmacologic agents. But the 
search for medications that act directly on the injury and sequelae to improve the 
outcome of TBI patients has been a long, expensive, and unsuccessful one. Hundreds of 
millions of dollars have been spent and thousands of subjects enrolled in clinical trials 
without a single proven-effective pharmacological intervention that specifically treats 
acute traumatic brain injury (National Institutes of Health, 2015; Narayan et al., 2002). 
 The purpose of the present investigation is to evaluate the effect of the hormone 
progesterone in a specific subtype of TBI, called traumatic subarachnoid hemorrhage 
(tSAH), that is found in a large number of moderate and severe TBI cases and has been 
shown to be a negative prognostic factor. This analysis was performed using the primary 
data from a recent nationwide phase III randomized controlled trial evaluating 
progesterone administration on the outcomes in traumatic brain injury.  
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II. LITERATURE REVIEW 
 
Overview  
 Traumatic brain injury is a major cause of death and disability, both in the United 
States and worldwide. Millions of individuals sustain TBIs every year and even more 
suffer from long-term effects from these injuries, costing tens of billions of dollars in 
care delivered and lost employment potential (Langlois et al., 2006). The specific type of 
TBI, traumatic subarachnoid hemorrhage, is both very common in more severe TBI 
(occurring in up to two-thirds of moderate and severe cases historically) and associated 
with poor outcome, with increased rates of mortality and unfavorable outcomes over 
patients without these injuries (Armin, Colohan, & Zhang, 2006, pp. 445–446).  
Brain injury research is exceptionally challenging due to many reasons, such as 
the difficulty in classifying a heterogeneous injury and the paucity of objective and 
clinically relevant endpoints. Many pharmacological agents have been studied to treat 
TBI and even a few specifically for tSAH, but none have been shown definitively to 
improve outcomes or lower mortality (Maas, Stocchetti, & Bullock, 2008, p. 736; Armin 
et al., 2006, p. 445). Significant differences exist between the etiology and 
pathophysiology of tSAH and those of aneurysmal subarachnoid hemorrhage (aSAH, 
subarachnoid hemorrhage of non-traumatic origin), but there are also meaningful 
similarities. Basic science tests in animal subarachnoid hemorrhage (SAH) models have 
findings that may translate to human subjects with tSAH (Armin et al., 2006, p. 448). 
The hormone progesterone, naturally occurring in both male and female bodies, 
has long held promise as a treatment for TBI, with extensive preclinical testing 
suggesting that it limits the detrimental secondary injuries sustained in TBI such as 
swelling and increased intracranial pressure. Subsequent research has supported the 
findings of two small human pilot trials investigating the efficacy of progesterone 
therapy for TBI (Espinoza & Wright, 2011). The Progesterone for Traumatic Brain 
Injury, Experimental Clinical Treatment (ProTECT III) trial, which began enrolling 
subjects in 2009, was the first phase III randomized controlled trial assessing the effect 
of progesterone in the setting of traumatic brain injury.  
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Existing literature provides theoretical reasoning that progesterone may have a 
different treatment effect in TBI patients with tSAH. This investigation analyzed 
ProTECT III trial data to evaluate if there is statistical interaction between progesterone 
and tSAH. An interaction would be suggested if there were a difference in the rates of 
favorable outcomes in the progesterone-treated subjects with tSAH over those without. 
This was assessed by measuring mortality and functional outcomes of patients and then 
performing a subgroup comparison based on treatment of progesterone or placebo.  
 
Epidemiology and cost of traumatic brain injury 
 
Traumatic brain injury (TBI) is an important public health problem…TBI is 
frequently referred to as the ‘silent epidemic’ because the complications from TBI, 
such as changes affecting thinking, sensation, language, or emotions, may not be 
readily apparent. In addition, awareness about TBI among the general public is 
limited. (Faul, Xu, Wald, & Coronado, 2010, p. 5) 
Over ten million traumatic brain injuries with the severity to cause death or 
hospitalization are estimated to occur worldwide every year (Hyder, Wunderlich, 
Puvanachandra, Gururaj, & Kobusingye, 2007). Considering that only a fraction of brain 
injuries are of the severity to necessitate hospitalization, the actual total global incidence 
of TBI is likely many times higher than this figure; no reliable point estimates of the 
worldwide prevalence of TBI could be found in a literature review. The World Health 
Organization estimates that “TBI is predicted to become the third leading cause of 
global mortality and disability by 2020” due to increasing rates of motor vehicle crashes 
(“The changing landscape of traumatic brain injury research,” 2012, p. 651). Though 
data from developing countries is sparse and possibly inaccurate, it suggests that low- 
and middle-income regions have a higher relative burden of injury from TBI than high-
income areas, thought to be in part due to lack of safety and health care infrastructure 
(Hyder et al., 2007, pp. 341–342). But even in the developed world, where subject 
literature is much more prevalent and reliable, it is clear that traumatic brain injury is a 
major public health problem.  
Based on the Centers for Disease Control and Prevention’s Morbidity and 
Mortality Weekly Report, of the estimated 1.7 million people who suffered a TBI each 
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year from 1997-2007 in the U.S., 1.4 million were seen and discharged from the 
emergency department (ED), 275,000 were hospitalized and survived, and 52,000 died 
(Coronado et al., 2011, pp. 1–2). Total prevalence is much higher—5.3 million 
Americans (~ 2% of the entire U.S. population or ~ 10% of those with any permanent 
disability) are estimated to be coping with long-term disability from a traumatic brain 
injury (Langlois et al., 2006, pp. 376–377). It is estimated that, in the U.S., someone 
suffers a TBI every 21 seconds (Hyder et al., 2007, p. 346). 
Although anyone (regardless of age, socioeconomic status, comorbidities, or other 
factors that typically influence risk) can be susceptible to traumatic injury, population-
level patterns certainly exist in TBI. Faul et al. (2010) synthesized the ED visitation, 
hospitalization, and mortality data of three national databases from 2002 to 2006 to 
compile the most comprehensive epidemiological analysis of TBI in the United States to 
date. They found those at highest risk for TBI are universally male (i.e. males are the 
majority of cases in all subgroups), making up 59% of all identified TBI cases (p.16). 
The gender disparity is much more lopsided in some subgroups, such as 20-34 year olds 
with fatal injuries, where greater than 80% of the victims are men (p. 38). As with many 
other diseases, the young and the old are especially vulnerable. Children aged 14 and 
younger make up almost 35% of all ED visits for TBI, and individuals 75 and older have 
the highest rates of hospitalization and death of all age groups (p. 7). Falls and motor 
vehicle collisions are the most likely causes of fatal injury, and TBI is estimated to 
contribute to one-third of all injury-related death (pp. 6-7). Importantly, this frequency 
data underestimates the actual burden of brain injury, as it does not include more than a 
half million patients. Anyone treated in medical settings outside of the hospital (e.g. 
primary care physician visits), any non-civilians (this report does not include data from 
federal, military, or VA hospitals), or any of the estimated 25% of TBI patients that seek 
no medical care at all, were not included in these figures (pp. 60-61).  
The implications of the epidemiology data are profound. Treating significant TBI 
in modern medical facilities is very expensive; Farhad et al. (2013) found that the 
average hospitalization for brain injury costs more than $20,000 and acute-care hospital 
bills can easily rise above $100,000 for the most severe patients (p. 85-86). And these 
treatment costs have skyrocketed—the same literature notes a 200% increase in the cost 
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of TBI hospitalization between 1993-1994 and 2006-2007, after adjustment for inflation 
(Farhad et al., 2013, pp. 85–89). Even “mild” brain injury can have enduring, 
debilitating, and sometimes even fatal effects; a prospective cohort study in the United 
Kingdom found that around half of brain injury patients aged 14 and over had moderate 
or severe disabilities after one year, regardless of the severity of the index injury 
(Thornhill et al., 2000, pp. 1631–1633). The spectrum of increasingly-intensive 
rehabilitation cost between $50,000 to almost a half of a million dollars per year in 
1991, and these figures are unadjusted for a subsequent quarter-century of inflation 
(Humphreys et al., 2013, p. 283). 
Not only can TBI profoundly change lives through physical disability and personal 
and familial financial hardships, but brain injury also has major economic impacts at the 
societal level. Just in the United States, the cost of acute TBI care and rehabilitation 
paired with the indirect costs of the lost earning potential of patients and other collateral 
economic effects are estimated at $60 billion per year (Langlois et al., 2006, p. 377). 
More recently, the CDC approximates this figure to be $76.5 billion (Manley & Maas, 
2013, p. 473). Though even rough estimates of the worldwide total cost of TBI are 
certainly very imprecise without more reliable epidemiologic data, extrapolating existing 
cost data to global frequency estimates likely puts the global economic impact of TBI in 
magnitude of hundreds of billions of dollars.  
 
Classification and pathophysiology of TBI  
 Substantial research effort has gone into mitigating the immense burden of TBI, 
but it remains an exceedingly complex area of study and clinical trials are fraught with 
obstacles in the search for effective treatment (Saatman et al., 2008, p. 720). The term 
“traumatic brain injury” is actually a catchall phrase, representing a host of 
fundamentally distinct physical insults. There are several major phenotypes of brain 
injury, such as hematomas (collection of blood) and axonal injury (shearing of neuronal 
cells). These subtypes of TBI vary in the mechanical forces required to inflict them, the 
structural damage which occurs to the affected brain cells, the pathophysiological 
sequelae occurring as a result of the injury, and the prognosis of the patient (Saatman et 
al., 2008; Zhu, Wang, & Liu, 2009).  
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 Most clinical trials to date have classified severity of brain injury by a mental 
status assessment called the Glasgow Coma Scale (GCS), which measures verbal 
response, eye opening, and motor response of the patient and compiles the three 
components into a score from 3 to 15 (Teasdale & Jennett, 1974). The GCS is performed 
soon after injury and a lower score represents a more depressed level of consciousness 
and, consequently, a more severe brain injury. “Mild,” “moderate,” and “severe” brain 
injury correspond to GCS assessments of 13-15, 9-12, and 3-8, respectively (Teasdale et 
al., 2014). According to a workshop described by Saatman et al. (2008), the use of the 
GCS has been prevalent due to “its high inter-observer reliability and generally good 
prognostic capabilities” (p.721). Despite being simple, fast, and therefore relatively easy 
for clinicians to use, the biggest problem with using the GCS to select patients for TBI 
research is that it does not discriminate between injuries that are classified differently 
using other methods, potentially confounding the assessment of treatments while other 
methods of classification “may be more relevant to the neuroprotectant action of a 
particular intervention” (Saatman et al., 2008, p. 721).  
 The literature by Saatman et al. (2008) reviews TBI classification systems for use 
in clinical trials, providing alternative methods of brain injury classification to the GCS 
include pathoanotomic, pathophysiologic, and prognostic models (p. 720). 
Pathoanotomic classification distinguishes between the type and location of injury. 
Primarily using imaging diagnostics such as computed tomography (CT) or magnetic 
resonance (MR), this method categorizes injuries into four basic types: hematomas 
(including epidural, subdural, and intraparenchymal—each are lesions in different 
structural areas of the brain), contusions (bruising of the brain tissue), diffuse axonal 
injury, or subarachnoid hemorrhage (pp. 722-724). Evidence suggests that mechanism of 
injury is correlated with the phenotype of injury sustained; linear and rotational forces 
damage the physical structures of the brain differently. “Impact loading,” or contact 
forces, usually produce fractures, contusions, and epidural hematomas, while “inertial 
loading,” or noncontact forces, are theoretically more likely to cause concussion, 
subdural hematomas, and axonal injury (p. 723). 
Pathophysiologic classification, very simply put, distinguishes between “primary 
injury,” or the direct insult to the brain from the index external force, and “secondary 
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injury,” or damage occurring to the brain as a result of the complex injury cascades after 
the initial structural damage like swelling and vasospasm (constriction of blood vessels) 
(p.724). It is this “potentially avoidable damage that occurs at variable times after 
injury” that research efforts have attempted to target for pharmacological treatment 
(p.723).  
Finally, prognostic classification uses complex multivariate statistical modeling to 
choose the factors with the strongest associations with outcomes to create a hybridized 
scoring system like the International Mission for Prognosis and Analysis of Clinical 
Trials in TBI (IMPACT) model, which uses data points from demographics, clinical 
assessments, brain imaging, and laboratory values to predict outcome in TBI (pp. 732-
733). 
 
Other obstacles in TBI research and past clinical trials 
 Leading neurotrauma researchers believe that historical and contemporary 
attempts to translate basic science findings into human clinical research have failed in 
part due to the inadequacy of prevalent classification systems and an inability to develop 
effective methodology to account for the heterogeneity of TBI (Yue et al., 2013). A 
multitude of other obstacles exist in clinical trials for brain injury. Randomized 
controlled trials (RCTs) are considered to be the “gold standard” in pharmacological 
efficacy trials, yet they are very expensive to conduct and research funding is limited 
(Roozenbeek, Lingsma, & Maas, 2012). Lack of standardization of data elements 
between trials limits the ability to combine data sets to achieve higher statistical power 
for post hoc analyses (Maas et al., 2011, p. 178). Typical outcome measures specific to 
TBI can be subjective and prone to bias and significant inter-rater variability. Other 
outcome assessments, such as neuropsychological tests, were not developed or validated 
for use in TBI patients. Outcomes measured at 6-months (the predominant follow-up 
time point in most TBI RCTs) are not taking into account long-term functional outcome, 
which have shown that many problems or improvements are still manifest up to three 
years from injury (van Baalen et al., 2003). Lastly, the Glasgow Outcome Scale (GOS) 
and its successor, the Extended Glasgow Outcome Scale (GOSE), the primary outcome 
measure used most frequently in brain injury clinical trials, may be inadequate in 
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assessing cognitive outcome and often are analyzed in ways that fail to maximize 
statistical power (Alali et al., 2014, pp. 1–2). 
 As a result of these factors along with inadequate preclinical testing, flawed study 
design, and insufficient evaluation of pharmacological biomechanics to target the 
complex cascade of secondary brain injury have lead to a veritable graveyard of 
experimental clinical trials in TBI (Kabadi & Faden, 2014, pp. 1216–1219). At least 33 
phase III clinical trials have been performed for traumatic brain injury since 1980, the 
majority of which tested a pharmacological agent (Maas, Roozenbeek, & Manley, 2010, 
p. 116). In total, none of the more than 20 promising neuroprotective agents “have 
convincingly shown efficacy in the overall study population” for the treatment of TBI 
(Maas et al., 2008, p. 736). Several trials have evaluated efficacy of two drugs, 
milrinone and nimodipine, specifically in the subgroup of TBI with traumatic 
subarachnoid hemorrhage (tSAH), but conclusive benefit has not been shown for either 
agent in the treatment of tSAH (Lasry & Marcoux, 2014; Vergouwen, Vermeulen, & 
Roos, 2006). Despite the obvious negative of the inability to find a treatment for the 
injury that continues to kill and disable so many, the consistent failure of 
pharmacological TBI clinical trials seems to be hindering the further development of 
investigations despite promising new agents (Maas et al., 2010, p. 119). 
 
Progesterone for the treatment of TBI 
 Long thought to be “a simple reproductive hormone” on account of its dramatic 
rise in females during gestation, the neurosteroid progesterone has been studied 
extensively in the context of TBI (Donald G. Stein & Wright, 2010, p. 849). 
Progesterone was first identified as having a potential effect in brain injured rats more 
than 20 years ago, after disparities in outcomes were seen relative to gender (Roof, 
Duvdevani, & Stein, 1992). Evidence suggests that progesterone acts in multiple ways to 
ameliorate sequelae of the complex biochemical chain of events that make up secondary 
brain injury. This pleiotropic effect of the hormone gave rise to the hope that it would 
succeed where many, more specifically-acting therapies had previously failed (Espinoza 
& Wright, 2011, pp. 497–498).  
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Briefly, progesterone has been shown in basic science tests to reduce cerebral 
edema, enhance neuronal survival, attenuate inflammatory pathways, reduce oxidative 
stress, and modulate receptor pathways, leading to improved functional outcome and 
limiting “behavioral, cognitive, and sensorimotor deficits” (Deutsch et al., 2013, pp. 88–
89). The hormone was evaluated in over 180 preclinical brain injury trials and two phase 
II human trials (where it was deemed safe to continue with further testing) prior to the 
large clinical trials of ProTECT III and the Study of the Neuroprotective Activity of 
Progesterone in Severe Traumatic Brain Injuries, or SyNAPSE trial (D.G. Stein, 2011, 
pp. 104–105). Two other pilot trials of progesterone in humans with TBI were found in 
the literature, in addition to those mentioned by Stein (2011). Those trials also suggest 
that progesterone may improve outcomes in brain injured patients (Xiao et al., 2007; 
Shakeri et al., 2013). 
 
ProTECT III and SyNAPSE trials 
The ProTECT III study was a National Institute of Neurological Disorders and 
Stroke (NINDS)-funded clinical trial to determine if progesterone is effective in 
improving outcomes in moderate and severe TBI. Subjects included had an initial GCS 
between 4 and 12 while those with confounding events, such as significant hypoxia (low 
oxygen) or hypotension (low blood pressure) or signs such as two dilated and unreactive 
pupils (all of which are prognosticators of poor outcomes), were excluded. Because the 
ProTECT pilot trial suggested that subjects receiving progesterone most quickly might 
have the best response to the intervention, study treatment was delivered within four 
hours after the injury.  
Subjects were monitored closely throughout their hospitalization, and treatment 
teams adhered (as closely as possible) to clinical care guidelines with the hopes of 
standardizing treatment and minimizing variability in the almost 50 sites nationwide that 
participated in the trial. The primary outcome for the trial was the 6-month GOSE 
assessment, and results were stratified to account for severity of initial injury. 
Enrollment for the trial was halted after randomizing 882 subjects, out of the planned 
sample of 1140, on account of futility to prove its primary hypothesis. Progesterone was 
not found to have a significant effect on the outcomes of moderate and severe traumatic 
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brain injury patients (Wright et al., 2014). Beginning enrollment one year after 
ProTECT III, the SyNAPSE trial was similarly structured except that it enrolled only 
severe TBI patients (those with a GCS ≤ 8). This research also did not show significant 
benefit for the intervention to improve outcomes in the study sample (Skolnick et al., 
2014). Primary analyses for these trials were published together in the New England 
Journal of Medicine in December of 2014. 
 
Traumatic subarachnoid hemorrhage  
 The arachnoid mater is one of the three meningeal layers of the brain, which lie 
underneath the skull and cover the brain cortex. Cerebrospinal fluid normally circulates 
in the space below the arachnoid mater. If there is hemorrhagic insult to the vasculature 
surrounding the brain, blood can collect there, hence the name of subarachnoid 
hemorrhage (SAH) (Bear, 2007, pp. 173–174). There are many different etiologies for 
SAH, but the two main causes are aneurysmal (as it is usually due to the rupture of an 
aneurysm), or as a result of trauma (aSAH and tSAH, respectively) (Suarez, Tarr, & 
Selman, 2006, p. 387). The medical community refers to and studies these two 
classifications of SAH as different diseases, though evidence suggests they have 
pathologic characteristics in common such as vasospasm and ischemia (decreased 
oxygen delivery to tissue) (Fukuda, Hasue, & Ito, 1998; Taneda, Kataoka, Akai, Asai, & 
Sakata, 1996). In previous studies, tSAH is seen on initial brain imaging between 33 and 
67 percent of severe head injury patients (Kakarieka, Braakman, & Schakel, 1994, p. 2; 
Bobinski, Olivecrona, & Koskinen, 2012, p. 1072). 
 Though there is much variation in the literature of the prevalence of this specific 
finding, it is not the only inconsistency in tSAH-specific research. As with general study 
of TBI, assessments of the pathophysiology of tSAH are confounded on account of 
concomitant injuries and other covariates (Armin et al., 2006, p. 446). The correlation of 
tSAH and worsened outcomes, however, seems to be universal. A host of manuscripts 
exist supporting this association in brain-injured patients; one investigation saw a rise in 
mortality in severe TBI patients from 14% to 42% from those that did not have evidence 
of tSAH to those that did (Kakarieka et al., 1994, p. 3). But there is disagreement on 
whether this relationship is directly or indirectly caused by the tSAH itself (Mattioli et 
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al., 2003, p. 40). Conflicting data is responsible for this uncertainty, but two basic 
possibilities exist: tSAH is an independent prognosticator of outcome, or it is merely 
representative of a more severely injured patient and not responsible for increased 
morbidity and mortality outright (Armin et al., 2006, pp. 446-447). 
 Some of the early research in this area suggested that, as with aSAH, patients with 
tSAH are at risk for vasospasm and resultant cerebral ischemia—pathophysiology that 
would likely explain the worsened clinical outcomes in this population (Harders, 
Kakarieka, & Braakman, 1996, p. 82). Subsequent analysis has found associations 
between tSAH and more parenchymal damage, higher intracranial pressures, and 
inflammatory processes (such as swelling and edema), and concluded these sequelae are 
responsible for poorer outcomes in these patients rather than the tSAH or resultant 
vasospasm and ischemia itself (Servadei et al., 2002, p. 266). Recent review remains 
inconclusive exactly what role vasospasm plays in outcomes in tSAH patients (Kramer, 
Winer, Pease, Amar, & Mack, 2013, pp. 3–4). Even the most current literature 
acknowledges that the complex pathophysiology of secondary brain injury in tSAH 
remains incompletely understood, though relative certainty exists that tSAH is a 
prognosticator for poor outcomes (Servadei & Picetti, 2014 pp. e597-e598). 
 
Theoretical basis for hypothesis 
 As previously mentioned, the literature supports beneficial effects of progesterone 
administration in the setting of brain injury as well as a host of other neurological 
conditions “including ischemia, spinal cord injury, peripheral nerve injury, motorneuron 
disease, demyelinating disease, and seizures” (Deutsch et al., 2013, p. 83). Though none 
of the six clinical trials studying progesterone in TBI found in the literature have 
specifically assessed tSAH until now, a number of studies have investigated 
progesterone’s effect in SAH in animal models. Although these studies were designed to 
assess the affects of progesterone in aSAH, it is recognized that aSAH is not 
pathophysiologically identical to tSAH with clinically meaningful differences between 
the two conditions. It also cannot be assumed there is no translation of findings 
whatsoever from aSAH to tSAH. Furthermore, Armin et al. (2006) assert, “the 
traditional animal experiments that had originally sought to investigate vasospasm in 
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relation to aSAH may be considered to actually have been mimicking tSAH” (p. 448). 
Another review concluded that tSAH was the most reproducible of five different lesion 
types in multiple animal models of injury (Doppenberg, Choi, & Bullock, 2004, p. 87). 
Although the exact characteristics and effects of vasospasm in tSAH require 
further evaluation, it is generally agreed that it does occur; one estimate of prevalence of 
vasospasm in tSAH to be between 25-30% of patients (Fukuda et al., 1998, p. 1044). 
Progesterone has been shown to significantly attenuate vasospasm in rats with induced 
aSAH (Chang et al., 2014). If vasospasm is contributing, at least in part, to worsened 
outcomes in tSAH, then it is possible that progesterone may benefit this population. But 
it is progesterone’s varied and multiple mechanisms of neuroprotection that set it apart 
from most of the other experimental pharmacologic agents, which have more limited 
methods of action. 
In addition to acting on vasospasm, progesterone ameliorates secondary injuries 
frequently found in tSAH. Wang et al. (2011) showed that, through complicated 
biochemical processes, progesterone affects the inflammatory response after the 
induction of SAH (p. 4). Thus this had important and clinically relevant effects on 
outcomes. Rats given progesterone showed statistically significant improvement on 
behavior function performance after SAH. Water content of the brains was significantly 
less in the progesterone-treated group, suggesting that cerebral edema (a common and 
potentially sinister finding in SAH and TBI in general) may be lessened by the 
intervention. Finally, this research demonstrated that progesterone significantly limits 
the permeability which develops in the blood-brain barrier (BBB) (pp. 6–8).  The BBB 
is a specialization of the capillaries of the brain that regulate the passage of molecules 
from the blood into the brain, thus prohibiting the entry of bacteria and other blood 
borne substances (Bear, 2007, p. 71). In fact, cerebral edema and the disruption of the 
BBB are likely directly related (Unterberg, Stover, Kress, & Kiening, 2004). A more 
recent study confirmed the findings of the previous investigations into the effects of 
progesterone in the setting of SAH in the animal model, finding a reduction in cell 
apoptosis (“self destruction” of cells, put simply), edema, BBB disruption, and 
mortality, with improved neurological and functional outcomes in those that survived 
(Yan et al., 2013, pp. 165–167).  
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The preclinical evidence regarding progesterone in SAH shows promise for the 
intervention to improve functional outcomes and decrease mortality in TBI patients if 
these mechanisms translate to humans. If the theories of how progesterone acts to reduce 
secondary brain injury are correct, then perhaps progesterone will be effective in an 
analysis of the subgroup with tSAH findings on initial brain imaging in the ProTECT III 
clinical trial data, despite the negative findings of the drug in the total study sample. 
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III. MANUSCRIPT 
 
Background 
 Traumatic brain injury (TBI) is a major cause of death and disability; approximately 
1.7 million people sustain a TBI every year in the United States—52,000 of these injuries 
are fatal.1 Indirect and direct costs of TBI in America are estimated to be $60-75 billion 
per year.2,3 Research of interventions for acute care of TBI is difficult, largely due to the 
heterogeneity of injury and complex pathophysiology of neurotrauma.4 At least 20 
pharmacological agents have been tested in phase III clinical trials over the last 30 years 
and none have shown convincing efficacy in treating TBI.5 
Radiological findings of subarachnoid hemorrhage (SAH), or blood in the 
subarachnoid meningeal space, on initial computed tomography (CT) imaging are found 
in one- to two-thirds of more severely brain-injured patients.6,7 The presence of 
subarachnoid hemorrhage caused by trauma (tSAH) is associated with increased 
mortality 6,8,9 and worsened functional outcome,10–13 though there is still uncertainty if 
tSAH is an independent prognosticator (possibly through mechanisms such as 
vasospasm14 or ischemia15) or an epiphenomenon.16,17  
The endogenous hormone, progesterone (PROG), has been evaluated in over 180 
preclinical brain injury studies showing neuroprotection.18 Four human pilot trials19–22 
have showed that PROG may improve outcomes in TBI, but these trials were not 
powered for conclusive results. Evidence suggests that PROG is pleiotropic, acting 
through multiple neuroprotective mechanisms to attenuate several characteristics of 
secondary brain injury associated with both SAH and worsened clinical outcomes in 
animal models. PROG has been shown ameliorate several sequelae of tSAH in preclinical 
studies: reduction of vasospasm,23 decreased inflammatory response, cerebral edema, and 
permeability of the blood-brain barrier,24 and limitation of cell apoptosis,25 all of which 
reduce mortality and improve functional and neurological outcomes after SAH. 
Two recent phase III trials failed to show benefit of PROG over placebo for study 
subjects with a severe or moderate-to-severe TBI.26,27 As of this writing, no published 
studies were found that investigate PROG specifically for the treatment of SAH of either 
traumatic or non-traumatic etiology in humans. This exploratory analysis of data 
collected in the Progesterone for Traumatic Brain Injury Experimental Clinical Treatment 
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(ProTECT III) study, a multicenter randomized controlled trial, is in response to this gap 
in the science. Since PROG may exert a different mechanism of action in TBI with tSAH 
due to changes in cellular pathophysiology and the blood-brain barrier, the objective of 
the present study is to determine if the effect of PROG administration in subjects with 
moderate and severe TBI is different in those with evidence of tSAH on baseline CT 
radiology compared to subjects without tSAH.  
 
Methods 
Design & participants 
This analysis is a post hoc examination of trial data from the 
ProTECT III clinical trial.26 Eight hundred eighty-two subjects, out of 
the planned sample of 1140, were enrolled in the study before 
recruitment was halted when a scheduled interim analysis determined 
it would not be able to show PROG efficacious for the treatment of 
study subjects with a moderate or severe TBI. See Appendix 1 for the 
ProTECT III protocol summary. 
Subjects included in this analysis were adults with a blunt 
mechanism TBI and an initial Glasgow Coma Scale (GCS) of 4 to 12. 
The GCS is a mental status assessment that judges eye, verbal, and 
motor response—these 3 components are summed to reach the total GCS score, a 
composite number from 3 to 15. A lower score represents more severe brain injury 
(Figure 1). This scale was developed specifically to quantify TBI severity,28 but its use 
has become common for all types of patients in emergency departments and intensive 
care units worldwide and has high predictive capabilities and inter-rater reliability.29 
As is typical with trauma patients suspected of having a TBI, all of the subjects in 
this study received a CT scan as soon as possible after arrival at the enrolling trauma 
center. An independent neuroradiologist assessed all images and documented any 
findings indicative of acute brain injury in the study database (see Supplement 1 for the 
radiology case report form from the trial). Major phenotypes of injury assessed (in 
addition to tSAH) were epidural, subdural, and intraparenchymal hematomas, brain 
contusions, diffuse axonal injury, and cranial fractures. Secondary injury characteristics 
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documented were signs of increased intracranial pressure, cerebral edema, or localized 
swelling.  
All ProTECT III subjects with at least one abnormality noted on baseline CT were 
included in the present analysis. Those subjects in the parent trial that had no 
abnormalities on initial brain imaging or missing this scan altogether were excluded from 
the current study. The total sample, participants with abnormal radiological findings, was 
labeled CT positive (+CT). +CT subjects were then divided into two subgroups by 
presence or absence of the independent variable in question for this analysis, tSAH. 
Subjects were included in the tSAH positive (+tSAH) group if their radiology showed 
any evidence of subarachnoid blood defined as hemorrhage of any severity in one or 
more of the locations assessed (the suprasellar or basal cisterns; the Sylvian, 
interhemispheric, or lobar fissures; or the ventricular system). Subjects in the tSAH 
negative group (–tSAH) had no instance of any of the findings above. Any other 
abnormal CT findings had no bearing on subgroup allocation and +tSAH or –tSAH 
subjects could have any combination of concomitant injuries evident on baseline CT. 
Each subgroup was further divided upon which study treatment subjects received, PROG 
or placebo. Figure 2 is a diagram detailing the sample selection in the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	  2.	  Study	  Sample	  Diagram	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Intervention 
Study medication was administered as soon as possible after enrollment, but within 
4 hours. Progesterone and placebo were identical in appearance and packaging.  
Treatment infused for 96 hours, starting with a one-hour loading dose, then a 71-hour 
maintenance dose, and finally a 3-tiered taper with 8 hours at each step until the infusion 
was complete.  
 
Outcome and other measurements 
The GOSE assessment was used as the primary outcome for this study. It ranks the 
functional outcome of brain injury patients into one 
of eight different categories30 (Figure 3). There are 
different statistical models used to analyze this 
measurement,31 but we chose a fixed dichotomy, 
which classifies a GOSE score of ≤ 4 as unfavorable 
and 5 or above as favorable, or more functionally 
capable. This method was chosen based on convention,31 historical statistical distribution 
of outcomes,5 improved generalizability of results,32 and that covariate adjustment in 
well-balanced subgroups of RCTs is not likely to significantly change the results from an 
unadjusted model.33 
Other classification systems used in this report are as follows. The Abbreviated 
Injury Scale (AIS) is an ordinal measurement from 1 to 6 for each of nine body regions.34 
It is based on severity and location of injury and a score of 1 represents minor injury 
while 6 is a fatal injury). The Injury Severity Score (ISS) is directly computed from the 
AIS, squaring the highest 3 values; a score of 75 is the maximum.34 Finally, the 
Rotterdam CT classification is a prognostic assessment (also 1 to 6, with a higher score 
correlating with increased mortality) developed in part to account for the strong 
prognostic value of tSAH and improve the accuracy of previously-existing predictive 
models for outcome in TBI.35,36 Other variables known to correlate with outcome in TBI 
that were considered in this analysis are age, GCS, pupil reactivity,37 significant post-
injury hypoxia or hypotension38, and the presence of polytrauma (significant injuries in 
multiple body systems).39  
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Randomization 
Subjects were randomized to treatment group either PROG or placebo, in a 1:1 
ratio. Age and GCS were factored into randomization scheme in order to assure even 
population of initial risk stratifications and gross age distribution between treatment 
groups. Randomization assignment was double-blinded so that none of the clinicians or 
researchers, in addition to subjects or their friends and family, knew which treatment 
study participants were receiving. Blinding remained throughout the study 
 
Statistical analysis 
We compared patient characteristics by treatment assignment to assess the 
distribution of covariates; comparisons were performed for all eligible participants and by 
tSAH classification. Risk ratios (RRs) and 95% confidence intervals (CI) were calculated 
based on the number of subjects with a favorable outcome relative to PROG for each 
subsample. Subjects missing outcome data were excluded entirely from the analysis. For 
the primary analysis, we compared the effect of progesterone on risk of favorable 
outcome by tSAH classification to assess interaction. In secondary analyses, we used 
Poisson log regression to estimate an adjusted RR, controlling for covariates. Variables 
included in the regression analysis were chosen based on uneven treatment distribution at 
baseline regarding prognostic and clinical characteristics: age, race, mechanism of injury, 
and pre-randomization hypotension were included in the adjusted regression model. 
 
Results 
Of the 882 subjects enrolled in the ProTECT III trial, 756 had abnormalities present 
on baseline CT images; 125 were excluded from analysis because abnormalities were not 
present, and one subject did not have an image collected. Five hundred eighty-two 
subjects, or 66% of all of the subjects in the parent trial, had evidence of tSAH on CT. 
Treatment group prevalence within the +tSAH and –tSAH subgroups was even to within 
5%. Table 1 shows demographic distributions, causative mechanism for TBI, and mean  
times from injury across the subgroups (since receiving expedient care and timely 
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delivery to the hospital is beneficial to outcome for neurotrauma patients).40 
The median age in the +tSAH group was 39 (range 17-93) compared to a median of 30 in 
the -tSAH group (range 17-94) and 36 among all enrolled participants (range 17-94). 
Gender distribution was almost exactly the same for all groups—males outnumbered 
females nearly 3 to 1. The largest variations were shown between treatment groups in the 
mechanisms of injury and in the smaller –tSAH group where age and race were 
substantially different (Table 2). 
Injury severity was greater in the +tSAH group over the –tSAH group by all 
classification systems reported; absolute differences of +tSAH minus –tSAH were 
GCS, -0.6; AIS, +0.4; Rotterdam, +1.1; and mean ISS, +3.7 (Table 3). All subgroups and 
the entire sample had mean Injury Severity Scores (ISS) well above 15, typically  
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considered the standard threshold for polytrauma.39 Concomitant intracranial injuries 
were largely disparate in the two subgroups, with the +tSAH group having greater 
prevalence of all other main categories of abnormalities assessed on baseline CT. These 
findings ranged from a 2.2% increase of diffuse axonal injury in +tSAH over –tSAH to 
an almost 19% higher frequency of cerebral edema. Even in the –tSAH group, although 
less-severely injured as a whole, showed particularly high numbers of subdural 
hematomas (SDH) and skull fractures, occurring in approximately half of the subgroup 
sample.  
Injury distributions between the treatment assignments were within 5% in the 
+tSAH group for all phenotypes. The PROG-treated subjects in the –tSAH group had 
5.5% more skull fractures, 6% more brain contusions, and 12.6% more SDHs (Table 4). 
All severity classifications however, were nearly identical between treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
 
+tSAH subjects did markedly worse than -tSAH, with an almost 27% shift from 
favorable to unfavorable outcome between the groups (Table 5). +tSAH subjects had a 
10.3% higher mortality rate than –tSAH subjects, and 2.4% more than total sample. 
Although modest improvements in favorable outcomes were seen in the PROG treatment 
group between subgroups (1.4% increase in absolute rate of favorable outcome of +tSAH 
over –tSAH), mortality was also higher in the PROG-treated subjects regardless of 
grouping (+tSAH 2.7%, –tSAH 2.3%, +CT 2.1%; Table 6 & Figure 4). 
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The RRs in Table 7 show progesterone had a modest favorable effect in both the 
unadjusted and adjusted analyses. In the unadjusted analysis, the risk of a favorable 
outcome with PROG in the +tSAH group is 1.06 times that of subjects receiving placebo 
(95% CI 0.89 to 1.26). Risk for favorable outcome in the –tSAH group for PROG was 
1.02 (95% CI 0.85 to 1.22) times that of subjects receiving placebo. After adjustment, 
RRs show that the risk of a favorable outcome of +tSAH patients treated with PROG to 
be 1.07 times that of placebo; PROG-treated subjects had 1.08 times the risk of a 
favorable outcome in the –tSAH group, but not +CT (and less absolute difference 
between all groups). However, these RRs were not statistically significant. 
 
 
 
 
 
 
Discussion 
Overall, we found +tSAH patients receiving progesterone therapy had a 2.8% 
greater likelihood of favorable outcome compared to +tSAH patients receiving placebo. 
Favorable outcome for PROG-treated subjects was 1.4% and 1.9% more likely in the      
–tSAH and +CT groups (respectively). Unadjusted estimates of relative benefit of PROG 
are 1.06 over placebo for +tSAH and 1.02 in the –tSAH sample. The small differences 
measured in treatment effect are not enough to suggest that tSAH changes the effect of 
progesterone in the treatment of TBI as postulated.  
Mortality rates of subjects with tSAH on brain imaging in this analysis (23%) are 
comparable to those in a 2006 systematic review of nimodipine for the treatment of 
tSAH39 (26%), although a smaller proportion of participants experienced an unfavorable 
outcome compared to what we report in the present study (40% vs. 53%). This 
discrepancy is likely due to differences in inclusion criteria between the studies, and the 
authors did not detail the characteristics that made patients eligible for enrollment. The 
review did not show a significant treatment effect of nimodipine in tSAH. Another 
investigation of milrinone specifically for vasospasm in tSAH41 was not powered to draw 
any worthwhile conclusions. With 756 subjects, our study was the largest single analysis 
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found in the clinical trial literature evaluating an intervention specifically in the setting of 
tSAH (the next largest was the unpublished HIT 4 trial with 577 subjects42). 
Some differences present in the distribution of baseline patient characteristics in this 
study could be meaningful. The –tSAH group was younger than the rest of the sample 
and, within this smaller subgroup, there was a large age difference between the treatment 
assignments. Age has been shown to be a specific and powerful measure for outcome in 
brain injury.36 Additionally, given recent literature suggesting that tSAH patients in 
motor vehicle collisions may have poorer outcomes than those that fall from height (> 3 
feet),43 it is reasonable to adjust for the mechanism of injury in the multivariate analysis 
given variability in frequencies across treatment groups. Two related conclusions can be 
drawn from the evenness of subgroup and treatment groups with regards to most of the 
key prognosticators, injury patterns, and even subjects with missing outcome: 
randomization of the parent trial was very effective, and minimal (if any) adjustment 
should be necessary to answer the research question proposed. 
If the unadjusted model is believed to be the most reliable computation (with even 
sample distribution as exhibited here), then it is possible that additional research, 
potentially in a prospective trial design, could be considered to further examine the 
possibility that PROG could improve outcome in patients with tSAH on baseline CT 
imaging. Of course the possibility that PROG may increase mortality should also be 
considered (although any adjustment for neurological vs. non-neurological [i.e. subject 
died from something else than TBI] was not factored into this analysis). 
The basic prevalence of +tSAH and –tSAH in this analysis supports previously 
existing research findings that tSAH incidence is disproportionate among more-severely 
injured TBI patients.6,7 However, the statistical models used here did not attempt to 
determine the underlying reason for this imbalance and no inferences can be made 
regarding why rates of favorable outcomes are lower in patients with evidence of tSAH 
on CT imaging from these data from those without signs of the injury. Obviously, it is 
expected that more severe TBI and higher prevalence of concomitant injuries will lead to 
poorer outcome. But it remains unanswered whether tSAH is an independent cause of 
worsened outcomes (possibly by associated secondary brain injury), or only correlated 
with other structural damages that are the responsible factors.  
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The present study has several important limitations worth noting. First, 
interpretation of subgroup analyses not specified in the original trial design should be 
critical due to a host of publicized issues such as low power, inappropriate statistical 
models, potential for type I error, and assumptive conclusions.44,45 Nonetheless, TBI is a 
heterogeneous disease with multiple underlying pathologies and there was biologic 
plausibility for our research question in the context of exploratory analysis and 
hypothesis generation. We did not perform a statistical interaction test because it was 
likely to result in misleading results or misinterpretation of its p-value in this post hoc 
subgroup analysis.33,46 Due to the fact that this study was exploratory with the intention 
of generating a hypothesis rather than testing one, clinical care recommendations or 
treatment guidelines should not be drawn from this analysis. Second, potentially 
important confounding covariates were not included in this analysis and, if there were 
large differences in treatment distribution, it is possible that our effect estimates were 
biased. For example, although the ProTECT III trial attempted to control treatment 
variability with clinical care guidelines for study subjects, significant differences have 
been found in previous studies between trial enrolling sites.38 No consideration was made 
here to assess or account for discrepancies between hospitals that were unlikely to have 
occurred by chance, if they indeed exist in the parent trial data. Also, significant 
complications in the patients’ hospital course can drastically effect outcome; although 
data regarding severe adverse events and deviations from treatment guidelines were 
collected, these data had not yet been properly processed at the time of the present 
analysis and thus could not be included herein. Third, subsequent imaging was also not 
included in this analysis, but could reveal important findings not visible on baseline CT 
such as diffuse axonal injury or hemorrhage expansion likely to be detrimental to the 
patient’s condition.  
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Conclusion 
In addition to the recent trials investigating PROG for TBI that showed no benefit 
in improving patient outcome, this study also suggests no significant treatment effect of 
PROG for tSAH. Although there was improvement shown in a dichotomous 6-month 
GOSE assessment to subjects given PROG in all groups in this analysis, this was not 
significant nor was an interaction effect noted between PROG and tSAH, as postulated in 
the objective for this study. Additional analyses should be performed using the full 
transgression and adverse event data, serial biomarker levels, and post-baseline imaging 
data to attempt to better determine why patients with tSAH have such poor outcomes 
when compared to those without the injury. Further research is needed to explore possible 
mitigators of secondary damage and other causes of worsened outcome in individuals 
suffering from acute brain injury as a result of trauma. 
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___ ___ - ___ ___ ___ - ___ ___ ___ ___    
(dd-mmm-yyyy) 
Date of assessment 
Data Collected? 
O No       O Yes 
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1 Date of scan        __ __ - __ __ __ - __ __ __ __   (dd-mmm-yyyy)  
2 Time of scan        __ __ : __ __   (24 hour clock hh:mm)  
3 What type of scan was performed?  O MRI       O CT         O CTA 
4 Was the scan technically satisfactory?  O No        O Yes   
5 Were there any abnormal findings? If no, form is complete  O No        O Yes  
Intracranial Bleeding  
6 Were there any epidural hematoma findings?  If no, skip to 12.  O No        O Yes  
Epidural Hematoma—Frontal  
7A Frontal - Left? O No        O Yes  
7B Frontal - Left Depth  __ __ __   (mm) 
7C Frontal - Left Width __ __ __   (mm) 
7D Frontal - Right? O No        O Yes  
7E Frontal - Right Depth    __ __ __   (mm) 
7F Frontal - Right Width  __ __ __   (mm) 
Epidural Hematoma—Temporal 
8A Temporal - Left? O No        O Yes  
8B Temporal - Left Depth  __ __ __   (mm) 
8C Temporal - Left Width __ __ __   (mm) 
8D Temporal  - Right? O No        O Yes  
8E Temporal  - Right Depth    __ __ __   (mm) 
8F Temporal  - Right Width  __ __ __   (mm) 
Epidural Hematoma—Parietal 
9A Parietal -  Left? O No        O Yes  
9B Parietal  - Left Depth  __ __ __   (mm) 
9C Parietal  - Left Width __ __ __   (mm) 
9D Parietal  - Right? O No        O Yes  
9E Parietal   - Right Depth    __ __ __   (mm) 
9F Parietal  -  Right Width  __ __ __   (mm) 
 
Form 03: Radiology Assessment– Central Reader (version 3)  
Sc n rec iv ? 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Epidural Hematoma—Occipital 
10A Occipital - Left? O No        O Yes  
10B Occipital - Left Depth  __ __ __   (mm) 
10C Occipital - Left Width __ __ __   (mm) 
10D Occipital  - Right? O No        O Yes  
10E Occipital  - Right Depth    __ __ __   (mm) 
10F Occipital  - Right Width  __ __ __   (mm) 
Epidural Hematoma—Posterior fossa 
11A Posterior fossa -  Left? O No        O Yes  
11B Posterior fossa   - Left Depth  __ __ __   (mm) 
11C Posterior fossa   - Left Width __ __ __   (mm) 
11D Posterior fossa   - Right? O No        O Yes  
11E Posterior fossa    - Right Depth    __ __ __   (mm) 
11F Posterior fossa   -  Right Width  __ __ __   (mm) 
12 Were there any subdural hematoma findings? If no, skip to 19 O No        O Yes  
Subdural Hematoma—Frontal  
13A Frontal - Left? O No        O Yes  
13B Frontal - Left Depth  __ __ __   (mm) 
13C Frontal - Left Width __ __ __   (mm) 
13D Frontal - Right? O No        O Yes  
13E Frontal - Right Depth    __ __ __   (mm) 
13F Frontal - Right Width  __ __ __   (mm) 
14A Temporal - Left? O No        O Yes  
14B Temporal - Left Depth  __ __ __   (mm) 
14C Temporal - Left Width __ __ __   (mm) 
14D Temporal  - Right? O No        O Yes  
14E Temporal  - Right Depth    __ __ __   (mm) 
14F Temporal  - Right Width  __ __ __   (mm) 
Subdural Hematoma—Temporal 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Subdural Hematoma—Parietal 
15A Parietal -  Left? O No        O Yes  
15B Parietal  - Left Depth  __ __ __   (mm) 
15C Parietal  - Left Width __ __ __   (mm) 
15D Parietal  - Right? O No        O Yes  
15E Parietal   - Right Depth    __ __ __   (mm) 
15F Parietal  -  Right Width  __ __ __   (mm) 
Subdural Hematoma—Occipital 
16A Occipital - Left? O No        O Yes  
16B Occipital - Left Depth  __ __ __   (mm) 
16C Occipital - Left Width __ __ __   (mm) 
16D Occipital  - Right? O No        O Yes  
16E Occipital  - Right Depth    __ __ __   (mm) 
16F Occipital  - Right Width  __ __ __   (mm) 
Subdural Hematoma—Posterior fossa 
17A Posterior fossa -  Left? O No        O Yes  
17B Posterior fossa   - Left Depth  __ __ __   (mm) 
17C Posterior fossa   - Left Width __ __ __   (mm) 
17D Posterior fossa   - Right? O No        O Yes  
17E Posterior fossa    - Right Depth    __ __ __   (mm) 
17F Posterior fossa   -  Right Width  __ __ __   (mm) 
Subdural Hematoma—Tentorial 
18 Tentorial O No        O Yes  
19 Were there subarachnoid hemorrhage findings? If no skip to question 29. O No        O Yes  
Subarachnoid Hemorrhage - Suprasellar 
20B Suprasellar - Present?  O No        O Yes  
20C Suprasellar - Fisher Grade   O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
Subarachnoid Hemorrhage - Basal Cisterns 
21B Basal Cisterns - Present? O No        O Yes  
21C Basal Cisterns - Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Subarachnoid Hemorrhage - Sylvian fissure 
22B Sylvian fissure - Left?  O No        O Yes  
22C Sylvian fissure - Left Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
22D Sylvian fissure - Right?  O No        O Yes  
22E Sylvian fissure - Right Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
Subarachnoid Hemorrhage - Interhemispheric 
23B Interhemispheric- Left?  O No        O Yes  
23C Interhemispheric- Left Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
23D Interhemispheric- Right?  O No        O Yes  
23E Interhemispheric- Right Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
Subarachnoid Hemorrhage - Lobar - frontal 
24B Lobar - frontal- Left?  O No        O Yes  
24C Lobar - frontal- Left Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
24D Lobar - frontal- Right?  O No        O Yes  
24E Lobar - frontal- Right Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
Subarachnoid Hemorrhage - Lobar - parietal 
25B Lobar - parietal- Left?  O No        O Yes  
25C Lobar - parietal- Left Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
25D Lobar - parietal- Right?  O No        O Yes  
25E Lobar - parietal- Right Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
26B Lobar - occipital- Left?  O No        O Yes  
26C Lobar - occipital- Left Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
26D Lobar - occipital- Right?  O No        O Yes  
26E Lobar - occipital- Right Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
Subarachnoid Hemorrhage - Lobar - occipital 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Subarachnoid Hemorrhage - Lobar - temporal 
27B Lobar - temporal- Left?  O No        O Yes  
27C Lobar - temporal- Left Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
27D Lobar - temporal- Right?  O No        O Yes  
27E Lobar - temporal- Right Fisher Grade O (2) < 1 mm thick          O (3) ≥ 1 mm thick 
28 Were there intra-ventricular hemorrhage findings? O No      O Yes, minimal layering    O Yes, clot  
29 Were there any intraparenchymal hematoma findings? If no, skip to 37. O No        O Yes  
Intraparenchymal Hematoma—Frontal  
30A Frontal - Left? O No        O Yes  
30B Frontal - Left Depth  __ __ __   (mm) 
30C Frontal - Left Width __ __ __   (mm) 
30D Frontal - Right? O No        O Yes  
30E Frontal - Right Depth    __ __ __   (mm) 
30F Frontal - Right Width  __ __ __   (mm) 
Intraparenchymal Hematoma—Temporal 
31A Temporal - Left? O No        O Yes  
31B Temporal - Left Depth  __ __ __   (mm) 
31C Temporal - Left Width __ __ __   (mm) 
31D Temporal  - Right? O No        O Yes  
31E Temporal  - Right Depth    __ __ __   (mm) 
31F Temporal  - Right Width  __ __ __   (mm) 
32A Parietal -  Left? O No        O Yes  
32B Parietal  - Left Depth  __ __ __   (mm) 
32C Parietal  - Left Width __ __ __   (mm) 
32D Parietal  - Right? O No        O Yes  
32E Parietal   - Right Depth    __ __ __   (mm) 
32F Parietal  -  Right Width  __ __ __   (mm) 
Intraparenchymal Hematoma—Parietal 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Intraparenchymal Hematoma—Occipital  
33A Occipital - Left? O No        O Yes  
33B Occipital - Left Depth  __ __ __   (mm) 
33C Occipital - Left Width __ __ __   (mm) 
33D Occipital - Right? O No        O Yes  
33E Occipital - Right Depth    __ __ __   (mm) 
33F Occipital - Right Width  __ __ __   (mm) 
Intraparenchymal Hematoma—Basal ganglia 
34A Basal ganglia- Left? O No        O Yes  
34B Basal ganglia- Left Depth  __ __ __   (mm) 
34C Basal ganglia- Left Width __ __ __   (mm) 
34D Basal ganglia- Right? O No        O Yes  
34E Basal ganglia- Right Depth    __ __ __   (mm) 
34F Basal ganglia- Right Width  __ __ __   (mm) 
Intraparenchymal Hematoma—Posterior fossa 
35A Posterior fossa -  Left? O No        O Yes  
35B Posterior fossa - Left Depth  __ __ __   (mm) 
35C Posterior fossa - Left Width __ __ __   (mm) 
35D Posterior fossa - Right? O No        O Yes  
35E Posterior fossa - Right Depth    __ __ __   (mm) 
35F Posterior fossa -  Right Width  __ __ __   (mm) 
Intraparenchymal Hematoma—Midbrain/pons 
36 Midbrain/pons O No        O Yes, 0-5 mm        O Yes, >5 mm 
37 Evidence of surgical evacuation?  O No        O Yes  
38 Were there any brain contusion findings? If no, skip to question 45. O No        O Yes  
39A Frontal - Left? O No        O Yes  
39B Frontal - Left Depth  __ __ __   (mm) 
39C Frontal - Left Width __ __ __   (mm) 
39D Frontal - Right? O No        O Yes  
39E Frontal - Right Depth    __ __ __   (mm) 
39F Frontal - Right Width  __ __ __   (mm) 
Brain Contusion—Frontal  
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Brain Contusion—Temporal 
40A Temporal - Left? O No        O Yes  
40B Temporal - Left Depth  __ __ __   (mm) 
40C Temporal - Left Width __ __ __   (mm) 
40D Temporal  - Right? O No        O Yes  
40E Temporal  - Right Depth    __ __ __   (mm) 
40F Temporal  - Right Width  __ __ __   (mm) 
Brain Contusion—Parietal 
41A Parietal -  Left? O No        O Yes  
41B Parietal  - Left Depth  __ __ __   (mm) 
41C Parietal  - Left Width __ __ __   (mm) 
41D Parietal  - Right? O No        O Yes  
41E Parietal   - Right Depth    __ __ __   (mm) 
41F Parietal  -  Right Width  __ __ __   (mm) 
Brain Contusion—Occipital  
42A Occipital - Left? O No        O Yes  
42B Occipital - Left Depth  __ __ __   (mm) 
42C Occipital - Left Width __ __ __   (mm) 
42D Occipital - Right? O No        O Yes  
42E Occipital - Right Depth    __ __ __   (mm) 
42F Occipital - Right Width  __ __ __   (mm) 
Brain Contusion—Basal ganglia 
43A Basal ganglia- Left? O No        O Yes  
43B Basal ganglia- Left Depth  __ __ __   (mm) 
43C Basal ganglia- Left Width __ __ __   (mm) 
43D Basal ganglia- Right? O No        O Yes  
43E Basal ganglia- Right Depth    __ __ __   (mm) 
43F Basal ganglia- Right Width  __ __ __   (mm) 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Brain Contusion—Posterior fossa 
44A Posterior fossa - Left? O No        O Yes  
44B Posterior fossa - Left Depth  __ __ __   (mm) 
44C Posterior fossa - Left Width __ __ __   (mm) 
44D Posterior fossa - Right? O No        O Yes  
44E Posterior fossa - Right Depth    __ __ __   (mm) 
44F Posterior fossa - Right Width  __ __ __   (mm) 
45 Were there any DAI findings? If no, skip to question 51. O No        O Yes  
DAI—Frontal  
46A Frontal - Left? O No        O Yes  
46B Frontal - Left Depth  __ __ __   (mm) 
46C Frontal - Left Width __ __ __   (mm) 
46D Frontal - Right? O No        O Yes  
46E Frontal - Right Depth    __ __ __   (mm) 
46F Frontal - Right Width  __ __ __   (mm) 
DAI—Parietal 
47A Parietal -  Left? O No        O Yes  
47B Parietal  - Left Depth  __ __ __   (mm) 
47C Parietal  - Left Width __ __ __   (mm) 
47D Parietal  - Right? O No        O Yes  
47E Parietal   - Right Depth    __ __ __   (mm) 
47F Parietal  -  Right Width  __ __ __   (mm) 
48A Basal ganglia- Left? O No        O Yes  
48B Basal ganglia- Left Depth  __ __ __   (mm) 
48C Basal ganglia- Left Width __ __ __   (mm) 
48D Basal ganglia- Right? O No        O Yes  
48E Basal ganglia- Right Depth    __ __ __   (mm) 
48F Basal ganglia- Right Width  __ __ __   (mm) 
DAI—Basal ganglia 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
DAI—Brainstem 
49A Brainstem - Present? O No        O Yes  
49B Brainstem - Depth __ __ __   (mm) 
49C Brainstem - Width __ __ __   (mm) 
DAI—Corpus Callosum 
50A Corpus Callosum - Present? O No        O Yes  
50B Corpus Callosum - Depth __ __ __   (mm) 
50C Corpus Callosum - Width __ __ __   (mm) 
81A Centrum Semiovale - Left? O No        O Yes  
81B Centrum Semiovale - Left Severity O Mild     O Moderate     O Severe 
81C Centrum Semiovale - Right? O No        O Yes  
81D Centrum Semiovale - Right Severity O Mild     O Moderate     O Severe 
51 Were there any generalized edema findings? If no, skip to question 53 O No        O Yes  
Generalized Edema - Hemisphere 
52A Hemisphere - Left? O No        O Yes  
52B Hemisphere - Left Severity O Mild     O Moderate     O Severe 
52C Hemisphere - Right? O No        O Yes  
52D Hemisphere - Right Severity O Mild     O Moderate     O Severe 
53 Were there any focal swelling findings? If no, skip to question 59.  O No        O Yes  
Focal Swelling - Frontal  
54A Frontal - Left?  O No        O Yes  
54B Frontal - Left Severity O Mild     O Moderate     O Severe 
54C Frontal - Right?  O No        O Yes  
54D Frontal - Right Severity O Mild     O Moderate     O Severe 
Focal Swelling - Temporal 
55A Temporal - Left?  O No        O Yes  
55B Temporal - Left Severity O Mild     O Moderate     O Severe 
55C Temporal - Right?  O No        O Yes  
55D Temporal - Right Severity O Mild     O Moderate     O Severe 
DAI—Centrum Semiovale 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
Focal Swelling—Parietal 
56A Parietal - Left?  O No        O Yes  
56B Parietal - Left Severity O Mild     O Moderate     O Severe 
56C Parietal - Right?  O No        O Yes  
56D Parietal - Right Severity O Mild     O Moderate     O Severe 
Focal Swelling—Occipital  
57A Occipital - Left?  O No        O Yes  
57B Occipital - Left Severity O Mild     O Moderate     O Severe 
57C Occipital - Right?  O No        O Yes  
57D Occipital - Right Severity O Mild     O Moderate     O Severe 
58A Basal ganglia  - Left?  O No        O Yes  
58B Basal ganglia  - Left Severity O Mild     O Moderate     O Severe 
58C Basal ganglia  - Right?  O No        O Yes  
58D Basal ganglia  - Right Severity O Mild     O Moderate     O Severe 
Focal Swelling—Basal ganglia  
59 Were there any radiological signs of increased  ICP? If no, skip to question 71.  O No         O Yes  
60 Sulcal obliteration  O Left         O Right        O Both       O None 
61 Lateral ventricle compression O Left         O Right        O Both       O None 
62 Compression or obliteration of third ventricle and of basal cisterns   O No         O Yes 
63 Midline shift  O To the Left        O To the Right         O None 
64 If ‘midline shift, specify size  O 0-5mm                O > 5mm 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
65 Transtentorial herniation present? O No        O Yes   
66 Uncal herniation present? O No        O Yes   
67 Tonsillar herniation present? O No        O Yes   
68 Upward herniation present?   O No        O Yes   
69 Other radiologic sign of increased ICP present?  O No        O Yes   
70 If ’other radiologic sign of increased ICP’ specify:   
71 Were there additional intracranial findings? If no, skip to question 75.    O No        O Yes   
Additional Intracranial Findings - Pseudoaneurysm 
72A Pseudoaneurysm - Present? O No        O Yes   
72B Pseudoaneurysm - If Yes, check all that apply 
□ Right ICA     
□ Right VA     
□ Left ICA     
□ Left VA 
Additional Intracranial Findings - Dissection 
73A Dissection - Present? O No        O Yes   
73B Dissection - If Yes, check all that apply 
□ Right ICA     
□ Right VA     
□ Left ICA     
□ Left VA 
Additional Intracranial Findings - Infarction 
74A Infarction - Present? O No        O Yes   
74B Infarction - If Yes, check all that apply 
□ Right ICA     
□ Right VA     
□ Left ICA     
□ Left VA 
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Form 03: Radiology Assessment– Central Reader (version 3)  
 Sc n rec iv ? 
75A Was there a skull fracture - Left? O No        O Yes   
75B Was there a skull fracture - Right? O No        O Yes   
76 Depressed skull fracture O No        O Yes   
77 If [depressed skull fracture], is depression greater than the thickness of the skull? O No        O Yes   
78 Basilar skull fracture O No        O Yes   
79 Other skull fracture O No        O Yes   
80 If [other skull fracture], specify:  
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Protocol Summary - ProTECT™ III 
 
TITLE OF THE TRIAL  
 
Progesterone for the Treatment of Traumatic Brain Injury 
 
TRIAL OBJECTIVES 
 
Primary Objective 
 
Determine the efficacy of administering intravenous (IV) progesterone (initiated within 4 hours of injury and 
administered for 72 hours, followed by an additional 24 hour taper) versus placebo for treating victims of 
moderate to severe acute TBI (Glasgow coma scale score 12-4).  
 
Primary Hypothesis  
 
Progesterone will increase the proportion of patients with a favorable outcome by a 10% (absolute) difference, 
determined by the Glasgow Outcome Scale-Extended (GOSE) score at 6 months post injury when compared 
to placebo. Our primary outcome analysis of the GOSE will use a stratified dichotomy methodology for 
assessing improvement. This approach dichotomizes GOSE scores as “favorable” versus “not favorable”, 
based on the brain injury severity score measured at randomization (best pre-randomization GCS or iGCS). 
Patients with the most severe injury (iGCS 4-5) will have a favorable outcome if the GOSE is good to severe; 
patients with an intermediate severe injury (iGCS 6-8) will have a favorable outcome if the GOSE is good to 
moderate; and patients with a moderate injury (iGCS 9-12) will have a favorable outcome if the GOSE is good 
recovery. A maximum of 1140 patients will be randomized, adjusting for age, gender, injury severity and 
clinical site. 
 
Secondary Endpoints  
 
Examine the efficacy of IV progesterone vs. placebo for treating patients with moderate to severe acute TBI on 
additional 6 month outcomes: Mortality, Disability Rating Scale (DRS), cognitive, neurological and functional 
outcomes using a select battery of tests, and rates of adverse and serious adverse events.  
 
Ancillary Study – BIO-ProTECT 
 
The primary aim of this ancillary study is to determine whether elevated levels of serum biomarkers (including 
S100B, GFAP, UCH-L1, SBDP150), measured within 4 hours of TBI or at 24 and 48 hours after randomization, 
independently predict clinical outcome as measured by the Glasgow Outcome Scale Extended (GOS-E) at 6 
months. The secondary aim is to determine, in progesterone treated subjects, if there a correlation between 
steady state serum progesterone levels and serum levels of S100B, GFAP, UCH-L1, SBDP150 at 24 and 48 
hours after randomization, and whether progesterone levels predict those subjects with a favorable clinical 
response to the experimental treatment as determined by the primary outcome of the study. 
 
METHODOLOGY 
  
A double blind, randomized, placebo-controlled, multicenter clinical trial. 
 
INFUSION PERIOD 
 
Following a one hour loading dose, the study infusion (progesterone or placebo) will be administered as a 
continuous intravenous infusion for 71 hours, and then tapered over three additional 8-hour decrements to 
zero, for a total treatment duration of 96 hours.  
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NUMBER OF SUBJECTS (planned) 
 
The total sample size is 1140 subjects, calculated for a 1:1 randomization scheme with 85% power (feasible in 
terms of number needed to enroll, and well within the accepted margins for error) to detect a 10% absolute 
difference in outcomes between treatment groups at the two-sided α of 0.05. With these assumptions, we will 
need 462 subjects per group (expected favorable outcome is 50% in those receiving placebo and 60% in those 
given treatment) after accounting for 3 analyses (2 interim after approximately 33% and 67% of enrollment and 
1 final) and using O’Brien Fleming boundaries. Assuming a conservative non-adherence rate of 10% (due to 
withdrawal of consent during infusion and loss to follow-up), we will need a maximum of 1140 subjects to 
ensure sufficient power to achieve our study goals.  
 
NUMBER OF SITES (planned) 
 
The ProTECT™ III Clinical Trial will partner with The Neurological Emergencies Treatment Trials (NETT) 
network. The NETT is comprised of 17 Hubs, each consisting of several hospital complexes (Spokes).  
 
INVESTIGATIONAL PRODUCT (dose, mode of administration)  
 
Our current dose is 0.714 mg/kg bolus for 1 hour, followed by 0.5 mg/kg/hr for 71 hours, followed by a q 8 hour 
decrement taper (3 changes) to zero.  
 
TRIAL DURATION PER SUBJECT 
 
From trial entry until 6 months post injury.  
 
MAIN OUTCOMES 
 
Primary Outcome 
  
Our Primary Outcome will be GOSE 6 months post-injury. GOSE is the primary measure of functional outcome 
and incorporates mortality in the primary outcome. A positive trial means that the treatment improves the 
proportion of patients having a “favorable” outcome by 10% absolute value. Favorable outcome is defined as 
described in the following table.  
 
If the patient’s iGCS is: If the iMotor Score is: Then the favorable outcome is:
4-5 2-3 6 mo GOSE = severe, moderate, or good 
6-8 4-5 6 mo GOSE = moderate or good 
9-12  6 mo GOSE = good recovery 
 
Secondary Outcomes 
 
Secondary outcomes of interest include the effects of progesterone vs. placebo in patients with moderate to 
severe TBI on 6 month mortality, Disability Rating Scale score, cognitive and neurological function outcomes 
and the rates of adverse and serious adverse events.  
 
SAFETY MONITORING 
 
Adverse events will be defined and severity graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE). AEs will be submitted through the WebDCUTM and coded using MedDRA. Guidelines for 
report content and structure will be provided. All adverse events will be recorded for the first 7 days after 
enrollment (4 days of drug infusion and 3 days post infusion). Based on the reported potential risks of 
progesterone administration, several important risks were identified that could be associated with progesterone 
(serious thromboembolic events such as thrombotic myocardial infarction, pulmonary embolism, deep vein 
thrombosis, ischemic stroke; allergic reactions; marked liver function abnormalities; serious infections such as 
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pneumonia, sepsis, meningitis) and have labeled them as “potentially associate adverse events” (PAAE). 
Study personnel will evaluate subjects while in the hospital and at each telephone communication and follow-
up for the presence of PAAEs or SAEs using a pre-constructed checklist. Sites will record and report PAAEs 
and SAEs within 24 hours of discovery throughout the course of the subject’s participation (6 months).  
 
We have employed two independent medical safety monitors (IMSM) with extensive expertise to review the 
PAAEs and SAEs, and provide causality judgments. Together they will provide daily coverage for the 
ProTECT™ III trial. The IMSM will make a determination of causality and expectedness based on 
predetermined criteria. IMSM reports that are serious, unexpected, and study drug related (possibly, probably, 
or definitely) will immediately be sent to the ProTECT™ III PI and Project Manager, who will submit a 
MedWatch 3500A to the FDA. Reports will be routed to each institution’s IRB (via the CCC and institutional 
PIs). Other measures to safeguard the welfare of study subjects include a formal review of all deaths by the 
trauma outcomes review committee at each site and a regularly scheduled comprehensive review of all safety 
data and AB physiological measurements by an independent NIH appointed Data and Safety Monitoring Board 
(DSMB).  
 
STATISTICAL METHODS TO ANALYZE THE PRIMARY OUTCOME 
  
Outcome differences will be analyzed on the basis of intention-to-treat. To assess efficacy, the treatment 
groups will be compared with respect to the proportion of subjects with favorable outcome 6 months post 
randomization. The primary efficacy hypothesis is tested via generalized linear model relating the probability of 
a favorable outcome to the treatment, adjusting for three covariates - injury severity, gender, and age.  
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